Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 11/2026 March 15, 2026
- Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide March 14, 2026
- Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing March 13, 2026
- Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial March 13, 2026
Aspirin’s Role in Prostate Cancer Recurrence
/in Retrospective studies/by MaxDiscovery of WNT9B Gene Mutation Significantly Increases Prostate Cancer Risk
/in Observational/by MaxEcDNA and Prostate Cancer: A New Frontier in Understanding Resistance
/in Preclinical Research/by MaxHydrogel Breakthrough May Improve Cancer Vaccines
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxCaRe Trial Expands to Include Veterans
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxNew Study Targets Tumor Cell Clusters to Combat Metastasis
/in Not PCa related/by MaxPhase 1 Trial: Pocenbrodib, A New (AI Based) Approach for mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1/2 Study: Evofosfamide With Immune Checkpoint Inhibitors for Advanced Cancers
/in Clinical Trial, Metastatic, Phase 1/by Max